Summary
Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax’s clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.
Novavax Inc (NVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Novavax Amends Co-Development Agreement With PATH 12
Novavax Enters Into Co-Development Agreement With PATH 13
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 14
Licensing Agreements 15
Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 15
Isconova Expands Licensing Agreement With Crucell 16
Novavax Enters Into Licensing Agreement With LG Life Sciences 16
Equity Offering 17
Novavax Plans to Raise USD75 Million in Public Offering of Shares 17
Novavax Raises USD201.2 Million in Public Offering of Common Stock 18
Novavax Raises USD115 Million in Public Offering of Shares 20
Novavax Completes Public Offering Of Shares For US$100 Million 21
Novavax Completes Private Placement Of Shares For US$27 Million 22
Novavax Completes Private Placement Of Shares For US$12.2 Million 23
Debt Offering 24
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24
Acquisition 26
Novavax Completes Acquisition Of 97.4% Interest In Isconova 26
Isconova Acquires Nordic Vaccine 28
Novavax Inc - Key Competitors 29
Key Employees 30
Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 33
Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 34
Nov 09, 2016: Novavax Reports Third Quarter 2016 Financial Results 35
Aug 09, 2016: Novavax Reports Second Quarter 2016 Financial Results 37
May 04, 2016: Novavax Reports First Quarter 2016 Financial Results 39
Feb 29, 2016: Novavax Reports Fourth Quarter and Year-End 2015 Financial Results 41
Corporate Communications 43
May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 43
Mar 17, 2016: Novavax Announces Management Promotions 44
Product News 45
Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 45
Product Approvals 46
May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 46
Clinical Trials 47
Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Novavax Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Novavax Amends Co-Development Agreement With PATH 12
Novavax Enters Into Co-Development Agreement With PATH 13
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 14
Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 15
Isconova Expands Licensing Agreement With Crucell 16
Novavax Enters Into Licensing Agreement With LG Life Sciences 16
Novavax Plans to Raise USD75 Million in Public Offering of Shares 17
Novavax Raises USD201.2 Million in Public Offering of Common Stock 18
Novavax Raises USD115 Million in Public Offering of Shares 20
Novavax Completes Public Offering Of Shares For US$100 Million 21
Novavax Completes Private Placement Of Shares For US$27 Million 22
Novavax Completes Private Placement Of Shares For US$12.2 Million 23
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24
Novavax Completes Acquisition Of 97.4% Interest In Isconova 26
Isconova Acquires Nordic Vaccine 28
Novavax Inc, Key Competitors 29
Novavax Inc, Key Employees 30
Novavax Inc, Other Locations 32
Novavax Inc, Subsidiaries 32List of Figures
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10
